Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The study objective is to explore the efficacy, safety and tolerability of STX209 for
treatment of irritability in subjects with FSX. We hypothesize that STX209 will improve
irritability and other typical problem behaviors associated with fragile X syndrome. We also
hypothesize that STX209 will be safe and well tolerated.